---
search:
  boost: 2 
---

# Lipotropics

This is a subcategory of Cardiovascular Agents.

## Formulary

### Preferred

| Preferred                                  | Generic Name                              | Quantity | Time (Days) |
| :----------------------------------------- | :---------------------------------------- | :------: | :---------: |
| Atorvastatin <sup>QL</sup>                 | Atorvastatin Calcium Tab (all strengths   |   102    |     102     |
| Cholestyramine Regular, Light              |                                           |          |             |
| Colestipol Tab                             |                                           |          |             |
| Ezetimibe                                  |                                           |          |             |
| Fenofibrate 48 and 145mg Tab <sup>QL</sup> | Fenofibrate Tab 48 MG & 145 MG            |   102    |     102     |
| Gemfibrozil <sup>QL</sup>                  | Gemfibrozil Tab                           |   204    |     102     |
| Lovastatin <sup>QL</sup>                   | Lovastatin Tab (all strengths)            |   204    |     102     |
| Omega-3-Acid Ethyl Esters                  |                                           |          |             |
| Niacin IR, ER OTC <sup>QL</sup>            | Niacin ER Tab (all strengths excl 500 MG) |   204    |     102     |
| Niacin IR, ER OTC <sup>QL</sup>            | Niacin ER Tab 500 MG                      |   306    |     102     |
| Praluent <sup>PA</sup>                     |                                           |          |             |
| Pravastatin                                | Pravastatin Sodium (all strengths)        |   102    |     102     |
| Prevalite                                  |                                           |          |             |
| Repatha <sup>PA</sup>                      |                                           |          |             |
| Rosuvastatin <sup>QL</sup>                 | Rosuvastatin Calcium Tab (all strengths)  |   102    |     102     |
| Simvastatin <sup>QL</sup>                  | Simvastatin Tab (all strengths)           |   102    |     102     |

### Non-Preferred

| Non-Preferred                                       | Generic Name                                        |         Quantity          |        Time (Days)        |
| :-------------------------------------------------- | :-------------------------------------------------- | :-----------------------: | :-----------------------: |
| Altoprev                                            |                                                     |                           |                           |
| Amlodipine / Atorvastatin                           |                                                     |                           |                           |
| Colesevelam                                         |                                                     |                           |                           |
| Colestipol Granules                                 |                                                     |                           |                           |
| Ezetimibe / Simvastatin                             |                                                     |                           |                           |
| Ezallor                                             |                                                     |                           |                           |
| Fenofibrate Cap <sup>QL</sup>                       | Fenofibrate Cap (all strengths)                     | Determined pursuant to PA | Determined pursuant to PA |
| Fenofibrate 40, 54, 120 and 160mg Tab <sup>QL</sup> | Fenofibrate Tab (all strengths excl 48 MG & 145 MG) | Determined pursuant to PA | Determined pursuant to PA |
| Fenofibric Acid <sup>QL</sup>                       | Fenofibric Acid Tab (all strengths)                 | Determined pursuant to PA | Determined pursuant to PA |
| Fenofibric Acid DR <sup>QL</sup>                    | Choline Fenofibrate DR Cap (all strengths)          |            102            |            102            |
| Fluvastatin                                         |                                                     |                           |                           |
| Juxtapid                                            |                                                     |                           |                           |
| Livalo                                              |                                                     |                           |                           |
| Nexletol                                            |                                                     |                           |                           |
| Nexlizet                                            |                                                     |                           |                           |
| Niacin ER Tab <sup>QL</sup>                         | Niacin ER Tab (all strengths excl 200 MG)           |            204            |            102            |
| Niacin ER Tab <sup>QL</sup>                         | Niacin ER Tab 500 MG                                |            408            |            102            |
| Vascepa                                             |                                                     |                           |                           |
| Zypitamag                                           |                                                     |                           |                           |

## Authorizations

**Length of Authorizations**: See below

|                                           |          |
| ----------------------------------------- | -------- |
| Juxtapid (Initial)                        | 180 days |
| Vascepa, Lovaza, ACL inhibitors (Initial) | 84 days  |
| All others (Initial and Subsequent)       | 365 days |

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

- Must provide documentation of baseline labs **AND** have documented adherence to **90 days** of prescribed lipid lowering medications
- Must have had an inadequate clinical response of at least **90 days AND** unable to reach goal LDL-C (see below) despite treatment with maximally tolerated dose of highpotency statin and ezetimibe (or a clinical reason that these drugs cannot be utilized)

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Lovastatin ER (Altoprev), Pitavastatin (Livalo), Fluvastatin (Lescol)

Additional Lovastatin ER (Altoprev), Pitavastatin (Livalo), Fluvastatin (Lescol) Criteria

- Must have had an inadequate clinical response of at least **30 days** with **two preferred** drugs in the same drug class

### Colesevelam (Welchol)

Additional Criteria for Colesevelam (Welchol)

- Must provide documentation of a Type 2 Diabetes diagnosis

### Icosapent Ethyl (Vascepa)

Additional Icosapent Ethyl (Vascepa) Criteria

- Must provide documentation of baseline labs indicating triglyceride levels ≥500mg/dL after an inadequate clinical response to fibrates, niacin, and diet/exercise
- Must provide documentation of discontinuation of drugs known to increase triglyceride levels (i.e., beta blockers, thiazides, and estrogens), if clinically appropriate

### Lomitapide (Juxtapid) & ATP Citrate Lysase (ACL) Inhibitor

Additional Lomitapide (Juxtapid) & ATP Citrate Lysase (ACL) Inhibitor Criteria

- Must provide documentation of baseline labs **AND** have documented adherence to **90 days** of prescribed lipid lowering medications
- Must have had inadequate clinical response of at least **90 days AND** unable to reach goal LDL-C with high-potency statin, ezetimibe and PCSK9 inhibitor (or a clinical reason that these drugs cannot be utilized)

### Additional Information

- High potency statins: atorvastatin (Lipitor) 40-80mg & rosuvastatin (Crestor) 20-40mg
- LDL goals for **Familial Hypercholesterolemia** (includes Heterozygous & Homozygous FH): LDL ≤ 100mg/dL for adults or LDL ≤ 110mg/dL for those < 18 years of age
- LDL goals for **Clinical Atherosclerotic Cardiovascular Disease (ASCVD)**: LDL ≤ 70mg/dL

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=22)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=12)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
